PMID- 37951988
OWN - NLM
STAT- MEDLINE
DCOM- 20231113
LR  - 20231122
IS  - 2045-2322 (Electronic)
IS  - 2045-2322 (Linking)
VI  - 13
IP  - 1
DP  - 2023 Nov 11
TI  - A novel test for type-I allergy based on crosslink formation of immunoglobulin-E 
      receptors by allergen-specific immunoglobulin-E antibodies and an allergen.
PG  - 19676
LID - 10.1038/s41598-023-46730-8 [doi]
LID - 19676
AB  - Detection of allergen-specific immunoglobulin E (IgE) antibodies (Abs) in serum 
      would allow for screening of the causative allergen in patients with type-I 
      allergy. In this study, we developed a new assay method to detect 
      allergen-specific IgE Abs, which involved crosslinking the plural FcepsilonRIalpha 
      molecules with an allergen and detection using an amplified luminescence 
      proximity homogeneous assay (AlphaCL). First, the allergen concentration, bead 
      concentrations, and incubation time were optimized for the detection of 
      anti-2,4-dinitrophenyl (DNP) IgE Abs in buffer. Under optimal conditions, AlphaCL 
      was able to detect DNP-specific IgE Abs in simulated human serum at levels 
      comparable to those in serum from type-I allergic patients. When AlphaCL was used 
      to detect anti-DNP IgE Abs, no signal counts were obtained with the monovalent 
      allergen 2,4-dinitrophenylated poly-gamma-glutamic acid, whereas high signal counts 
      were obtained with the multivalent allergen DNP-BSA. This confirmed that AlphaCL 
      could specifically detect allergen-specific IgE Abs with the ability to crosslink 
      a multivalent allergen. In summary, we have established a new assay model using 
      AlphaCL to detect allergen-specific IgE Abs with FcepsilonRIalpha crosslinking ability in 
      human serum. This simple and practical assay model may be applied as a new 
      diagnostic tool for patients with type-I allergy.
CI  - (c) 2023. The Author(s).
FAU - Koga, Yuki
AU  - Koga Y
AD  - Department of Pharmaceutical Services, Graduate School of Biomedical and Health 
      Sciences, Hiroshima University, 1-2-3 Kasumi, Minami-ku, Hiroshima, 734-8553, 
      Japan.
FAU - Ishii, Soichiro
AU  - Ishii S
AD  - Department of Pharmaceutical Services, Graduate School of Biomedical and Health 
      Sciences, Hiroshima University, 1-2-3 Kasumi, Minami-ku, Hiroshima, 734-8553, 
      Japan.
FAU - Yokooji, Tomoharu
AU  - Yokooji T
AD  - Department of Pharmaceutical Services, Graduate School of Biomedical and Health 
      Sciences, Hiroshima University, 1-2-3 Kasumi, Minami-ku, Hiroshima, 734-8553, 
      Japan.
AD  - Department of Frontier Science for Pharmacotherapy, Graduate School of Biomedical 
      and Health Sciences, Hiroshima University, Hiroshima, Japan.
FAU - Yamamoto, Konomi
AU  - Yamamoto K
AD  - Department of Frontier Science for Pharmacotherapy, Graduate School of Biomedical 
      and Health Sciences, Hiroshima University, Hiroshima, Japan.
FAU - Ogino, Ryohei
AU  - Ogino R
AD  - Department of Frontier Science for Pharmacotherapy, Graduate School of Biomedical 
      and Health Sciences, Hiroshima University, Hiroshima, Japan.
FAU - Taogoshi, Takanori
AU  - Taogoshi T
AD  - Department of Pharmaceutical Services, Graduate School of Biomedical and Health 
      Sciences, Hiroshima University, 1-2-3 Kasumi, Minami-ku, Hiroshima, 734-8553, 
      Japan.
FAU - Matsuo, Hiroaki
AU  - Matsuo H
AD  - Department of Pharmaceutical Services, Graduate School of Biomedical and Health 
      Sciences, Hiroshima University, 1-2-3 Kasumi, Minami-ku, Hiroshima, 734-8553, 
      Japan. hmatsuo@hiroshima-u.ac.jp.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20231111
PL  - England
TA  - Sci Rep
JT  - Scientific reports
JID - 101563288
RN  - 0 (Allergens)
RN  - 0 (Receptors, IgE)
RN  - 37341-29-0 (Immunoglobulin E)
SB  - IM
MH  - Humans
MH  - Allergens
MH  - Receptors, IgE
MH  - Immunoglobulin E
MH  - *Hypersensitivity, Immediate
MH  - *Hypersensitivity
PMC - PMC10640595
COIS- The authors declare no competing interests.
EDAT- 2023/11/12 00:42
MHDA- 2023/11/13 06:42
PMCR- 2023/11/11
CRDT- 2023/11/11 23:29
PHST- 2023/07/06 00:00 [received]
PHST- 2023/11/04 00:00 [accepted]
PHST- 2023/11/13 06:42 [medline]
PHST- 2023/11/12 00:42 [pubmed]
PHST- 2023/11/11 23:29 [entrez]
PHST- 2023/11/11 00:00 [pmc-release]
AID - 10.1038/s41598-023-46730-8 [pii]
AID - 46730 [pii]
AID - 10.1038/s41598-023-46730-8 [doi]
PST - epublish
SO  - Sci Rep. 2023 Nov 11;13(1):19676. doi: 10.1038/s41598-023-46730-8.